S?ndromes mieloproliferativos cr?nicos

Jaffe, 2001 Dias, 2002, Vascular endothelial growth factor (VEGF) signaling through FLT-4 (VEGF-3) mediates leukemic cell proliferation, survival and resistance to chemotherapy, Blood, 99, 2179, 10.1182/blood.V99.6.2179 Heim, 1995, Cancer cytogenetics Vardiman, 2002, The World Health Organization (WHO) classification of the myeloid neoplasms, Blood, 100, 2292, 10.1182/blood-2002-04-1199 Silva, 1998, Expression of Bcl-x in erythroid precursors from patients with Polycythemia Vera, N Engl J Med, 338, 564, 10.1056/NEJM199802263380902 Kralovics, 2003, Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders, Blood, 102, 1869, 10.1182/blood-2003-03-0744 Klippel, 2001, Quantification of PRV-1 expression, a molecular marker for the diagnosis of polycythemia vera, Blood, 98, 470a Tefferi, 2004, Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia, Blood, 103, 3547, 10.1182/blood-2003-10-3505 Liu, 2003, Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin, Blood, 101, 3294, 10.1182/blood-2002-07-2287 Klippel, 2003, Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocitosis, Blood, 102, 3569, 10.1182/blood-2003-03-0919 Moliterno, 1998, Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia Vera, N Engl J Med, 338, 572, 10.1056/NEJM199802263380903 Fialkow, 1979, Clonal origin of human tumors, Annu Rev Med, 30, 135, 10.1146/annurev.me.30.020179.001031 Florensa, 1995, Endogenous megakaryocyte end erythroid colony formation from blood in essential thrombocythemia, Leukemia, 9, 271 Nowell, 1960, A minute chromosome in human CML, Science, 132, 1497 Rowley, 1973, A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine staining and Giemsa staining, Nature, 243, 290, 10.1038/243290a0 Faderl, 1999, The biology of chronic myeloid leukaemia, N Engl J Med, 341, 164, 10.1056/NEJM199907153410306 Deininger, 2000, The molecular biology of chronic myeloid leukaemia, Blood, 96, 3343, 10.1182/blood.V96.10.3343 Goldman, 2003, Mechanisms of disease: chronic myeloid leukemia: advances in biology and new approaches to treatment, N Engl J Med, 349, 1451, 10.1056/NEJMra020777 Lee, 2000, Chronic myelogenous Leukemia, Br J Haematol, 111, 993, 10.1046/j.1365-2141.2000.02216.x Spiers, 1977, The peripheral blood in chronic granulocytic leukaemia, Scand J Haematol, 18, 25, 10.1111/j.1600-0609.1977.tb01474.x Melo, 1996, The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype, Blood, 88, 2375, 10.1182/blood.V88.7.2375.bloodjournal8872375 Bain, 2003 Sinclair, 2000, Large deletions at the t(9;22)breakpoint are common and may identify a poor prognosis subgroup of patients with chronic myeloid leukaemia, Blood, 95, 738, 10.1182/blood.V95.3.738.003k21_738_743 Sokal, 1984, Prognostic discrimination in ?good-risk? chronic granulocytic leukaemia, Blood, 63, 789, 10.1182/blood.V63.4.789.789 1994, Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukaemia, N Engl J Med, 330, 820, 10.1056/NEJM199403243301204 Guilhot, 1997, Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukaemia, N Engl J Med, 337, 223, 10.1056/NEJM199707243370402 O?Brien, 2003, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia, N Engl J Med, 348, 904 Hughes, 2003, Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukaemia, N Engl J Med, 349, 1423, 10.1056/NEJMoa030513 Hochhaus, 2003, Cytogenetic and molecular mechanisms of resistance to imatinib, Semin Hematol, 40, 69, 10.1053/shem.2003.50045 Kantarjian, 2004, High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukaemia, Blood, 103, 2873, 10.1182/blood-2003-11-3800 Van Rhee, 1997, Long term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation, Bone Marrow Transpl, 20, 553, 10.1038/sj.bmt.1700933 Gratwohl, 1998, Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation, Lancet, 352, 1087, 10.1016/S0140-6736(98)03030-X Medina, 2003, Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase, Cancer, 9, 1905, 10.1002/cncr.11729 Reilly, 2002, Chronic neutrophilic leukemia: a distinct clinical entity?, Br J Haematol, 116, 10, 10.1046/j.1365-2141.2002.03234.x Spivak, 2002, Polycythemia vera: myths, mechanisms, and management, Blood, 100, 4272, 10.1182/blood-2001-12-0349 Prchal, 1974, Letter: Bone-marrow responses in polycythemia vera, N Engl J Med, 290, 1382, 10.1056/NEJM197406132902419 Adamson, 1980, Polycythemia vera. Further in vitro studies of hematopoietic regulation, J Clin Invest, 66, 1363, 10.1172/JCI109989 Menon, 2004, The Budd Chiari syndrome, N Engl J Med, 350, 578, 10.1056/NEJMra020282 Najfeld, 2002, Exploring polycythemia vera with FISH: additional cryptic 9p Is the most frequent abnormality detected, Br J Haematol, 119, 1, 10.1046/j.1365-2141.2002.03763.x Shin, 2002, Predictive values of X-chormosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocytemia, Blood, 100, 1596, 10.1182/blood.V100.5.1596.h81702001596_1596_1601 Berk, 1986, Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols, Semin Hematol, 23, 132 Berk, 1995, Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group, 166 Frutchman, 1997, From efficacy to safety: a polycythemia vera study group report on hydroxiurea in patients with polycythemia vera, Semin Hematol, 34, 17 Spivak, 2002, The optimal management of polycythemia vera, Br J Haematol, 116, 243, 10.1046/j.1365-2141.2002.03287.x Landolfi, 2004, N Engl J Med, 350, 114, 10.1056/NEJMoa035572 Stobart, 1994, Allogeneic bone marrow transplantation for an adolescent with polycythemia vera, Bone Marrow Transplant, 13, 337 Schafer, 2004, Thrombocytosis, N Engl J Med, 350, 1211, 10.1056/NEJMra035363 Besses, 2003, Trombocitemia esencial Griesshammer, 2004, PRV-1 mRNA expression discriminates two types of essential thrombocythemia, Ann Hematol, 83, 364, 10.1007/s00277-004-0864-9 Michielis, 1997, Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the polycythemia Vera Study Group, Semin Thromb Hemost, 23, 339, 10.1055/s-2007-996107 Barbui T, Finazzi G. Indications for cytorreductive therapya in polycythemia vera and essential thrombocythemia. ASH 2003. Tefferi, 2000, Myelofibrosis with myeloid metaplasia, N Engl J Med, 342, 1255, 10.1056/NEJM200004273421706 Lennert, 1975, Patho-anatomical features of the bone marrow in polycythemia and myelofibrosis, Clin Haematol, 4, 331, 10.1016/S0308-2261(21)00079-5 Cervantes F. Nuevas modalidades terap?uticas de la mielofibrosis idiop?tica. XLV Reuni?n Nacional de la AEHH. Brito-Babapulle, 2003, The eosnophilias, including the idiopathic hypereosinophilic syndrome, Br J Haematol, 121, 203, 10.1046/j.1365-2141.2003.04195.x Apperley, 2002, Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet derived growth factor receptor beta, N Engl J Med, 347, 481, 10.1056/NEJMoa020150 Cools, 2003, A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome, N Engl J Med, 348, 1201, 10.1056/NEJMoa025217